F-1/A: Mainz Biomed Seeks Up to $8 Million in Best Efforts Offering to Advance Cancer Detection Technology

Mainz Biomed N.V. is conducting a best-efforts offering of ordinary and pre-funded units to raise capital for its cancer detection technology development and commercialization.

Summary

• Mainz Biomed N.V., a Dutch company focused on developing in-vitro diagnostic tests for early cancer detection, is seeking to raise capital through a best-efforts offering.
• The offering includes up to 1,147,776 ordinary units, each consisting of one ordinary share, one Class A warrant, and one Class B warrant, and pre-funded units for investors who would exceed a 4.99% ownership threshold.
• The assumed offering price is $6.97 per ordinary unit, based on the closing price of the company's ordinary shares on December 6, 2024.
• The company intends to use the net proceeds for the eAArly Detect 2 study, development of its next-generation screening product, commercial expansion of ColoAlert, repayment of convertible debt, and general corporate purposes.
• Mainz Biomed's flagship product, ColoAlert, is a CE-IVD certified diagnostic test for colorectal cancer currently available in Europe.
• The company is also developing a next-generation mRNA-based colorectal cancer screening test and PancAlert, a product candidate for pancreatic cancer detection.
• Recent clinical studies, ColoFuture and eAArly DETECT, have shown promising results for the next-generation CRC screening test, with sensitivities of 92-97% for CRC and 80-82% for advanced adenomas.
• The company has partnered with Thermo Fisher Scientific to develop its mRNA-based assays on their platforms.
• Mainz Biomed is focusing on expanding its ColoAlert business in Europe, particularly in Germany, and plans to conduct the eAArly Detect 2 clinical study in the U.S. in 2025.
• The company has restructured its operations, reducing personnel by 65% and closing its European Oncology Lab to focus on core business activities.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While the company highlights positive clinical trial results and strategic partnerships, it also acknowledges significant financial risks, including operating losses, going concern issues, and the uncertainty of a best-efforts offering. The potential for dilution and the lack of a public market for warrants also contribute to a neutral to slightly negative sentiment.

Positives

• The company's next-generation mRNA-based CRC screening test has shown high sensitivity and specificity in clinical trials.
• The partnership with Thermo Fisher Scientific provides access to advanced technology and resources.
• Mainz Biomed is strategically focusing on core business activities and cost reduction.
• The company has a CE-IVD certified product, ColoAlert, already available in European markets.
• The company is targeting a large and growing market for colorectal cancer diagnostics, estimated to surpass $30 billion by 2032.
• The company has a clear strategy for commercial expansion in Europe, particularly in Germany.
• The company has a pipeline of products including PancAlert for pancreatic cancer detection.

Negatives

• The offering is on a best-efforts basis, with no guarantee of raising the desired capital.
• The company has incurred operating losses since inception and has substantial doubt about its ability to continue as a going concern.
• The market price of the company's ordinary shares has been volatile.
• Investors will experience immediate and substantial dilution as a result of the offering.
• There is no public market for the pre-funded warrants, Class A warrants, or Class B warrants.
• The company has been notified by Nasdaq that it is not in compliance with certain listing standards.
• The company has broad discretion in the use of the net proceeds from the offering.
• The company is subject to various complex laws and regulations, and non-compliance could result in fines and penalties.

Risks

• The company is an early revenue stage company and has incurred operating losses since inception.
• The company's financial statements include an explanatory paragraph from its auditor indicating substantial doubt about its ability to continue as a going concern.
• The company's success depends heavily on its ColoAlert screening tests.
• Sales of diagnostic tests could be impacted by physician reluctance and competing tests.
• The company may not succeed in establishing and maintaining its brands.
• The company may face technology transfer challenges and expenses in adding new tests and expanding geographically.
• The company may depend on future collaborations to develop and commercialize its diagnostic test candidates.
• The company may not be able to obtain and enforce patents and protect trade secrets.
• Results of FDA required studies may not create desired clinical performance.
• The market price of the company's ordinary shares may be volatile.
• The company may be delisted from Nasdaq if it does not regain compliance with listing requirements.
• The company has broad discretion in the use of the net proceeds from the offering.
• There is no public market for the pre-funded warrants, Class A Warrants and Class B Warrants being offered.

Future Outlook

The company intends to use the net proceeds from this offering for the eAArly Detect 2 study, the development of its next generation screening product, the commercial expansion of its ColoAlert product, repayment of convertible debt and for general corporate purposes. The company is also planning the eAArly Detect 2 clinical study in the U.S. in 2025.

Management Comments

• The company's mission is to enhance disease diagnosis by applying cutting-edge genetic diagnostic technologies, enabling earlier and more accurate detection for timely and improved treatment.
• The company believes that cost reductions will position the business for success in 2025 and beyond.

Industry Context

The company operates in the molecular diagnostics market, specifically focusing on colorectal and pancreatic cancer detection. The market for CRC diagnostics is anticipated to surpass $30 billion by 2032. The company is competing with other diagnostic tests and companies in this space, and is aiming to differentiate itself through its advanced mRNA-based technology and AI-driven algorithms.

Comparison to Industry Standards

• The document compares the sensitivity and specificity of Mainz Biomed's next-generation mRNA CRC screening test to competing products, including Cologuard, Exact Sciences, and Fecal Immunochemical Tests (FIT).
• Mainz Biomed's pooled study results show a CRC sensitivity of 92% and specificity of 90%, and an AA sensitivity of 82% and specificity of 90%.
• Cologuard has a reported CRC sensitivity of 92% and specificity of 87%, and an AA sensitivity of 42% and specificity of 90%.
• FIT tests have a reported CRC sensitivity of 68% and specificity of 95%, and an AA sensitivity of 24% and specificity of 95%.
• The document highlights that Mainz Biomed's test has a higher sensitivity for advanced adenomas compared to Cologuard and FIT tests.

Legal Proceedings

• Mainz filed a lawsuit against an investment bank in 2024 in the New York State Supreme Court in New York County.
• The investment bank initiated arbitration proceedings against Mainz with the Financial Industry Regulatory Authority (FINRA).
• The arbitration panel agreed to stay its proceeding in light of the existing lawsuit.

Stakeholder Impact

• Shareholders will experience immediate and substantial dilution as a result of the offering.
• Shareholders may face difficulties protecting their interests due to the company's incorporation in the Netherlands.
• Employees have been impacted by a 65% reduction in personnel.
• Customers may benefit from the development of more effective cancer screening tests.
• Creditors may be impacted by the company's repayment of convertible debt.

Next Steps

• The company plans to conduct the eAArly Detect 2 clinical study in the U.S. in 2025.
• The company will continue to develop its next-generation screening product.
• The company will focus on commercial expansion of ColoAlert in Europe, particularly in Germany.
• The company will make monthly payments towards the convertible debenture starting January 31, 2025.

Key Dates

Keywords

Colorectal Cancer, Cancer Screening, In-Vitro Diagnostics, mRNA Biomarkers, Molecular Diagnostics, PancAlert, ColoAlert, Best-Efforts Offering, Clinical Trials, Thermo Fisher Scientific, Reverse Stock Split, Nasdaq, Warrants, Pre-Funded Units